Interacciones de Prednisona

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (etiqueta de Abiraterona, Advertencias y precauciones)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

…Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine… (etiqueta de Adrenalina, Interacciones medicamentosas)

Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (etiqueta de Arformoterol, Contraindicaciones)

Coadministration of fluticasone propionate and REYATAZ with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects [see Warnings and Precautions (5.1) ] . (etiqueta de Atazanavir, Interacciones medicamentosas)

Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (etiqueta de Axitinib, Advertencias y precauciones)

Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Baricitinib, Advertencia en recuadro)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (etiqueta de Docetaxel, Advertencias y precauciones)

…(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (etiqueta de Emtricitabina, rilpivirina y tenofovir, Contraindicaciones)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Etanercept, Advertencia en recuadro)

Use of a LABA, including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1) ]. (etiqueta de Formoterol, Contraindicaciones)

Coadministration of fluticasone and fosamprenavir calcium/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (etiqueta de Fosamprenavir, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Infliximab, Advertencia en recuadro)

Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (etiqueta de Ketoconazol, Interacciones medicamentosas)

Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (etiqueta de Lovastatina, Contraindicaciones)

WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (etiqueta de Mifepristona, Advertencia en recuadro)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (etiqueta de Mitotano, Advertencia en recuadro)

None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (etiqueta de Moexipril, Advertencias)

Therefore, use of prednisone to prevent nevirapine-associated rash is not recommended. (etiqueta de Nevirapina, Advertencias y precauciones)

Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (etiqueta de Rilpivirina, Contraindicaciones)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (etiqueta de Salmeterol, Advertencia en recuadro)

In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (etiqueta de Sirolimus, Advertencias y precauciones)

Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (etiqueta de Somatropina, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Tocilizumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Tofacitinib, Advertencia en recuadro)

Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (etiqueta de Trandolapril, Advertencias)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etiqueta de Tretinoína, Advertencia en recuadro)

If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (etiqueta de Trióxido de arsénico, Advertencia en recuadro)

• use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (etiqueta de Umeclidinio y vilanterol, Contraindicaciones)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Oral Contraceptive Steroids Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction. (etiqueta de Ácido valproico, Interacciones medicamentosas)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etiqueta de Ácido zoledrónico, Advertencias y precauciones)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (etiqueta de Aclidinio, Interacciones medicamentosas)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (etiqueta de Afatinib, Advertencias y precauciones)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (etiqueta de Albendazol, Advertencias y precauciones)

Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (etiqueta de Alemtuzumab, Advertencias y precauciones)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (etiqueta de Alendronato, Advertencias y precauciones)

Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (etiqueta de Aliskireno, Advertencias y precauciones)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (etiqueta de Anfotericina B, Interacciones medicamentosas)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

In a detailed case report, 4 documented lymphopenia, diminished IgG and IgM levels, CMV infection, and a decreased thymic shadow were noted in an infant born to a mother receiving 150 mg azathioprine and 30 mg prednisone daily throughout pregnancy. (etiqueta de Azatioprina, Advertencias)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Hypercorticism and Adrenal Suppression QVAR REDIHALER will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (etiqueta de Beclometasona, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Belladona y opio, Advertencias y precauciones)

Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

• Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (etiqueta de Benralizumab, Advertencias y precauciones)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (etiqueta de Bictegravir, emtricitabina y tenofovir alafenamida, Interacciones medicamentosas)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with budesonide and formoterol fumarate dihydrate. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Buprenorfina, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Buprenorfina y naloxona, Advertencias y precauciones)

…risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse… (etiqueta de Bupropión, Advertencias y precauciones)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (etiqueta de Prednisona, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Butorfanol, Advertencias)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (etiqueta de Cefoxitina, Advertencias y precauciones)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during ALVESCO therapy [see Dosage and Administration ( 2 )] . (etiqueta de Ciclesonida, Advertencias y precauciones)

Cyclosporine: Increase in activity of both, cyclosporine and corticosteroid when administered concurrently. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Ciprofloxacino, Advertencias y precauciones)

Drug Interactions Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyldigoxin and chemotherapy regimens containing cyclophosphamide, vincristine and prednisone with or without cytarabine injection or procarbazine. (etiqueta de Citarabina, Interacciones medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etiqueta de Cladribina, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (etiqueta de Cocaína, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Codeína, Advertencias y precauciones)

Cholestyramine Cholestyramine may increase the clearance of corticosteroids. (etiqueta de Prednisona, Interacciones medicamentosas)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (etiqueta de Daptomicina, Advertencias y precauciones)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (etiqueta de Denosumab, Advertencias y precauciones)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (etiqueta de Dicicloverina, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Digitalis Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

…following drugs can be coadministered with dolutegravir without a dose adjustment: atazanavir/ritonavir, darunavir/ritonavir, elbasvir/grazoprevir, methadone, midazolam, omeprazole, oral contraceptives containing norgestimate and ethinyl estradiol, prednisone, rifabutin, rilpivirine, sofosbuvir/velpatasvir, and tenofovir [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Dolutegravir, Interacciones medicamentosas)

…treated with 6-mercaptopurine (500 mg/m 2 intravenously daily for 5 days per cycle every 2–3 weeks) and doxorubicin hydrochloride (50 mg/m 2 intravenous once per cycle every 2–3 weeks) alone or with vincristine and prednisone, all developed hepatic dysfunction manifested by increased total serum bilirubin, alkaline phosphatase and aspartate aminotransferase. (etiqueta de Doxorubicina, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (etiqueta de Prednisona, Interacciones medicamentosas)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (etiqueta de Elexacaftor, tezacaftor e ivacaftor, Advertencias y precauciones)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (etiqueta de Erlotinib, Advertencias y precauciones)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)

Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (etiqueta de Fenilbutirato de glicerol, Interacciones medicamentosas)

Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (etiqueta de Fenilbutirato de sodio, Interacciones medicamentosas)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (etiqueta de Fenilefrina, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Fentanilo, Advertencias y precauciones)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (etiqueta de Fingolimod, Advertencias y precauciones)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

The use of flunisolide with alternate-day prednisone systemic treatment could increase the likelihood of HPA suppression compared to a therapeutic dose of either one alone. (etiqueta de Flunisolida, Advertencias)

Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (etiqueta de Fluocinonida, Advertencias y precauciones)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with Fluticasone Propionate DISKUS. (etiqueta de Fluticasona, Advertencias y precauciones)

Hypercorticism and Adrenal Suppression Fluticasone propionate, a component of Fluticasone Propionate/Salmeterol MDPI, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (etiqueta de Fluticasona y salmeterol, Advertencias y precauciones)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids. (etiqueta de Halobetasol, Advertencias y precauciones)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (etiqueta de Haloperidol, Interacciones medicamentosas)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (etiqueta de Hidralazina, Advertencias)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona, Advertencias y precauciones)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona y clorfenamina, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona y homatropina, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona y paracetamol, Advertencias)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidromorfona, Advertencias y precauciones)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (etiqueta de Ibandronato, Advertencias y precauciones)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antitubercular Drugs Serum concentrations of isoniazid may be decreased. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (etiqueta de Ivermectina, Advertencias)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Levofloxacino, Advertencias y precauciones)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Levorfanol, Advertencias)

If the patient needs more doses of XOPENEX HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (etiqueta de Levosalbutamol, Advertencias y precauciones)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (etiqueta de Prednisona, Advertencias y precauciones)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (etiqueta de Prednisona, Advertencias y precauciones)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (etiqueta de Prednisona, Advertencias y precauciones)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. (etiqueta de Lisinopril e hidroclorotiazida, Advertencias)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (etiqueta de Margetuximab, Advertencias y precauciones)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Decrease corticosteroids gradually, if appropriate. (etiqueta de Mepolizumab, Advertencias y precauciones)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Metadona, Advertencias y precauciones)

Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (etiqueta de Metazolamida, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

If not, corticosteroids may be given and other causes of anemia should be considered. (etiqueta de Metildopa, Advertencias)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etiqueta de Metiltestosterona, Advertencias)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (etiqueta de Prednisona, Advertencias y precauciones)

This can be corrected by giving appropriate doses of corticosteroids. (etiqueta de Metirapona, Advertencias y precauciones)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (etiqueta de Prednisona, Interacciones medicamentosas)

Corticosteroids Or ACTH May increase the risk of hypokalemia and increase salt and water retention. (etiqueta de Metolazona, Interacciones medicamentosas)

NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (etiqueta de Metotrexato, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

In a randomized comparative trial of mitoxantrone injection plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone injection had a cardiac event defined as any decrease in LVEF below the normal range, congestive heart failure (n = 3), or myocardial ischemia. (etiqueta de Mitoxantrona, Advertencias)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Hypercorticism and Adrenal Suppression ASMANEX HFA will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (etiqueta de Mometasona, Advertencias y precauciones)

Inhaled corticosteroid may be reduced gradually. (etiqueta de Montelukast, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Morfina, Advertencias y precauciones)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Moxifloxacino, Advertencias y precauciones)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Nalbufina, Advertencias)

…hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended… (etiqueta de Naltrexona y bupropión, Advertencias y precauciones)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (etiqueta de Natalizumab, Advertencias y precauciones)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (etiqueta de Nintedanib, Advertencias y precauciones)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (etiqueta de Ocrelizumab, Advertencias y precauciones)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Ofloxacino, Advertencias)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oliceridina, Advertencias y precauciones)

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (etiqueta de Omalizumab, Advertencias y precauciones)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oxicodona, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oxicodona y paracetamol, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oximorfona, Advertencias y precauciones)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Paracetamol y codeína, Advertencias)

If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (etiqueta de Penicilamina, Advertencias)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Pentazocina y naloxona, Advertencias)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Petidina (meperidina), Advertencias y precauciones)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (etiqueta de Ponesimod, Advertencias y precauciones)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Published animal studies show prednisolone to be teratogenic in rats, rabbits, hamsters, and mice with increased incidence of cleft palate in offspring. (etiqueta de Prednisona, Advertencias y precauciones)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Prometazina y codeína, Advertencias y precauciones)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (etiqueta de Prednisona, Advertencias y precauciones)

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (etiqueta de Propofol, Advertencias y precauciones)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etiqueta de Risedronato, Advertencias y precauciones)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (etiqueta de Rocuronio, Advertencias y precauciones)

If the patient needs more doses of Albuterol Sulfate HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (etiqueta de Salbutamol, Advertencias y precauciones)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (etiqueta de Suxametonio (succinilcolina), Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone May decrease tacrolimus whole blood trough concentrations. (etiqueta de Tacrolimus, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Tapentadol, Advertencias y precauciones)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (etiqueta de Teofilina, Advertencias)

If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (etiqueta de Terbutalina, Advertencias)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (etiqueta de Prednisona, Advertencias y precauciones)

Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (etiqueta de Tesamorelina, Interacciones medicamentosas)

Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (etiqueta de Testosterona, Advertencias y precauciones)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (etiqueta de Tiotropio, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Corticosteroids and ACTH: Increased risk of hypokalemia. (etiqueta de Torasemida, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Tramadol, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Tramadol y paracetamol, Advertencias y precauciones)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

Other Considerations Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect. (etiqueta de Triamtereno e hidroclorotiazida, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (etiqueta de Prednisona, Interacciones medicamentosas)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (etiqueta de Zenocutuzumab, Advertencias y precauciones)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (etiqueta de Ácido bempedoico, Advertencias y precauciones)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (etiqueta de Alteplasa, Advertencias y precauciones)

Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (etiqueta de Amikacina, Advertencias y precauciones)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (etiqueta de Ampicilina, Advertencias)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etiqueta de Anfetamina, Interacciones medicamentosas)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etiqueta de Anfetamina y dexanfetamina, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etiqueta de Bevacizumab, Advertencias y precauciones)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

…50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin,… (etiqueta de Bortezomib, Advertencias y precauciones)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (etiqueta de Busulfano, Advertencias)

Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (etiqueta de Calcitriol, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Some subjects in the EPIDIOLEX clinical trials had pruritus, erythema, and angioedema requiring treatment, including corticosteroids and antihistamines. (etiqueta de Cannabidiol (con receta), Advertencias y precauciones)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefaclor, Advertencias)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefadroxilo, Advertencias y precauciones)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefdinir, Advertencias)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefotetán, Advertencias)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefprozilo, Advertencias)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Ceftazidima, Advertencias)

Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (etiqueta de Ceftriaxona, Advertencias y precauciones)

Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (etiqueta de Ciclosilicato de sodio y zirconio, Interacciones medicamentosas)

The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (etiqueta de Clofarabina, Advertencias y precauciones)

Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (etiqueta de Clomifeno, Advertencias)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (etiqueta de Corticotropina, Advertencias y precauciones)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etiqueta de Dexanfetamina, Interacciones medicamentosas)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisona, Interacciones medicamentosas)

These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (etiqueta de Droperidol, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisona, Interacciones medicamentosas)

Steroids may or may not be effective in controlling these hemolytic episodes. (etiqueta de Fludarabina, Advertencias y precauciones)

Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. (etiqueta de Prednisona, Advertencias y precauciones)

Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (etiqueta de Fluoxetina, Advertencias y precauciones)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisona, Interacciones medicamentosas)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (etiqueta de Guselkumab, Advertencias y precauciones)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Amphotericin B Injection There have been cases reported in which concomitant use of Amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure [see Drug Interactions (7.14) ] . (etiqueta de Prednisona, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (etiqueta de Lenalidomida, Advertencias y precauciones)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (etiqueta de Melfalán, Advertencias)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisona, Interacciones medicamentosas)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etiqueta de Metanfetamina, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Midodrine hydrochloride has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. (etiqueta de Midodrina, Interacciones medicamentosas)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (etiqueta de Naltrexona, Advertencias y precauciones)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisona, Interacciones medicamentosas)

Moderate and weak CYP3A4 inducers include, for example: amprenavir, aprepitant, armodafinil, bosentan, efavirnenz, etravirine, Echinacea, modafinil, nafcillin, pioglitazone, prednisone, rufinamide, and vemurafenib. (etiqueta de Nimodipino, Interacciones medicamentosas)

Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (etiqueta de Olanzapina y fluoxetina, Advertencias y precauciones)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (etiqueta de Oxacilina, Advertencias)

Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (etiqueta de Penicilina G, Advertencias)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (etiqueta de Penicilina V, Advertencias)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (etiqueta de Pilocarpina, Interacciones medicamentosas)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisona, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (etiqueta de Quinina, Interacciones medicamentosas)

Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Raloxifeno, Interacciones medicamentosas)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etiqueta de Rituximab, Advertencias y precauciones)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisona, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (etiqueta de Tenecteplasa, Advertencias y precauciones)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (etiqueta de Ustekinumab, Advertencias y precauciones)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisona, Interacciones medicamentosas)

Los corticosteroides como la prednisona reducen la absorción de calcio y alteran el metabolismo de la vitamina D, lo que contribuye a la pérdida de masa ósea. (NIH Office of Dietary Supplements, Vitamin D)

Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (etiqueta de Ziprasidona, Advertencias y precauciones)

…influenza vaccine ketoconazole lomefloxacin mebendazole medroxyprogesterone methylprednisolone metronidazole metoprolol nadolol nifedipine nizatidine norfloxacin ofloxacin omeprazole prednisone, prednisolone ranitidine rifabutin roxithromycin sorbitol (purgative doses do not inhibit theophylline absorption) sucralfate terbutaline, systemic terfenadine tetracycline… (etiqueta de Aminofilina, Interacciones medicamentosas)

Other Concomitant Drug Therapy Drug-drug interaction studies conducted in healthy subjects between zileuton immediate-release tablets and prednisone and ethinyl estradiol (oral contraceptive), drugs known to be metabolized by the CYP3A4 isoenzyme, have shown no significant interaction. (etiqueta de Zileutón, Interacciones medicamentosas)